GH

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health has seen its stock price move sharply in recent years, which puts fresh attention on whether the current valuation lines up with the cash the business can generate over time.

What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 93.5%, hitting $171.24. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

A Cancer Test Approval Meets a High Valuation Guardant Health, Inc. (NASDAQ:GH) is moving beyond identifying mutations at diagnosis toward testing patients repeatedly as their cancer changes.

Guardant Health (GH) is back in focus after new data on its Shield blood test for colorectal cancer screening and Guardant Reveal test for melanoma residual disease were released in October 2026.

Guardant Health (NasdaqGS:GH) lost a key U.S. patent challenge after the PTAB upheld all 30 claims of TwinStrand's '127 patent.

Guardant Health reported new data from its Shield blood-based colorectal cancer screening test, including modeling and rural clinic results, indicating very high real world adherence and meaningful impact on screening pathways for average risk adults.